1. Home
  2. AVLN vs QNST Comparison

AVLN vs QNST Comparison

Compare AVLN & QNST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

SELL

Current Price

$26.27

Market Cap

1.3B

Sector

Health Care

ML Signal

SELL

Logo QuinStreet Inc.

QNST

QuinStreet Inc.

HOLD

Current Price

$16.45

Market Cap

1.1B

ML Signal

HOLD

Company Overview

Basic Information
Metric
AVLN
QNST
Founded
2011
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
2026
2009

Fundamental Metrics

Financial Performance
Metric
AVLN
QNST
Price
$26.27
$16.45
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
6
Target Price
★ $61.80
$22.80
AVG Volume (30 Days)
266.3K
★ 734.6K
Earning Date
11-25-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 1650.00
EPS
N/A
★ 1.40
Revenue
N/A
★ $282,140,000.00
Revenue This Year
N/A
$15.97
Revenue Next Year
N/A
$8.55
P/E Ratio
★ N/A
$12.06
Revenue Growth
★ N/A
N/A
52 Week Low
$22.24
$10.29
52 Week High
$40.17
$22.29

Technical Indicators

Market Signals
Indicator
AVLN
QNST
Relative Strength Index (RSI) 45.32 52.07
Support Level $24.90 $14.09
Resistance Level $30.45 $18.02
Average True Range (ATR) 1.73 0.54
MACD 0.45 0.24
Stochastic Oscillator 72.23 69.92

Price Performance

Historical Comparison
AVLN
QNST

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

About QNST QuinStreet Inc.

QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. The company operates as one reportable segment. The company generates majority of revenue from United States. The company's products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and Cloud Control Media.

Share on Social Networks: